These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 32982184)

  • 1. Study Design Characteristics and Pharmacological Mechanisms in International Clinical Trials Registry Platform: Registered Clinical Trials on Antiviral Drugs for COVID-19.
    Zhang W; Lv Y; Yang J; Chen Y; He Y; Huang J
    Drug Des Devel Ther; 2020; 14():3803-3813. PubMed ID: 32982184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evidence mapping and analysis of registered COVID-19 clinical trials in China.
    Lu L; Li F; Wen H; Ge S; Zeng J; Luo W; Wang L; Tang C; Xu N
    BMC Med; 2020 Jun; 18(1):167. PubMed ID: 32493331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of COVID-19 Clinical Trials in China Based on the Registration Data on ChiCTR and ClinicalTrials.gov.
    Huang J; He Y; Su Q; Yang J
    Drug Des Devel Ther; 2020; 14():2159-2164. PubMed ID: 32581514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds.
    Tzou PL; Tao K; Nouhin J; Rhee SY; Hu BD; Pai S; Parkin N; Shafer RW
    Viruses; 2020 Sep; 12(9):. PubMed ID: 32916958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of trial registry entries for randomized clinical trials investigating COVID-19 medical prevention and treatment.
    Karlsen APH; Wiberg S; Laigaard J; Pedersen C; Rokamp KZ; Mathiesen O
    PLoS One; 2020; 15(8):e0237903. PubMed ID: 32817689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chloroquine and its derivatives in the management of COVID-19: A scoping review.
    Pimentel J; Andersson N
    Biomedica; 2020 Oct; 40(Supl. 2):80-95. PubMed ID: 33152192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
    Li J; Zhang C; Wu Z; Wang G; Zhao H
    Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Research methodology and characteristics of journal articles with original data, preprint articles and registered clinical trial protocols about COVID-19.
    Fidahic M; Nujic D; Runjic R; Civljak M; Markotic F; Lovric Makaric Z; Puljak L
    BMC Med Res Methodol; 2020 Jun; 20(1):161. PubMed ID: 32571302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
    Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
    Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and progress of clinical trials of Coronavirus Disease 2019 antiviral drugs.
    Pang W; Wang Q; Zhao Z
    Expert Rev Clin Pharmacol; 2020 Sep; 13(9):945-956. PubMed ID: 32729363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis.
    Mehta HB; Ehrhardt S; Moore TJ; Segal JB; Alexander GC
    BMJ Open; 2020 Jun; 10(6):e039978. PubMed ID: 32518212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of COVID-19 clinical trials registered with ClinicalTrials.gov: cross-sectional analysis.
    Jones CW; Woodford AL; Platts-Mills TF
    BMJ Open; 2020 Sep; 10(9):e041276. PubMed ID: 32948577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial.
    Takayama S; Namiki T; Ito T; Arita R; Nakae H; Kobayashi S; Yoshino T; Ishigami T; Tanaka K; Kainuma M; Nochioka K; Takagi A; Mimura M; Yamaguchi T; Ishii T
    Trials; 2020 Oct; 21(1):827. PubMed ID: 33008479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial.
    Saiz-Rodríguez M; Peña T; Lázaro L; González Á; Martínez A; Cordero JA; Vicente JT; Richard F; Coma MJ; de Frutos M; Labrador J; Pueyo A
    Trials; 2020 Jul; 21(1):632. PubMed ID: 32646502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2.
    Lisi L; Lacal PM; Barbaccia ML; Graziani G
    Biochem Pharmacol; 2020 Oct; 180():114169. PubMed ID: 32710969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of Anluohuaxian in the treatment of patients with severe Coronavirus disease 2019- a multicenter, open label, randomized controlled study: a structured summary of a study protocol for a randomised controlled trial.
    Zhang C; Li J; Wu Z; Wang H; Que C; Zhao H; Wang G
    Trials; 2020 Jun; 21(1):495. PubMed ID: 32513299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial.
    García IG; Rodriguez-Rubio M; Mariblanca AR; de Soto LM; García LD; Villatoro JM; Parada JQ; Meseguer ES; Rosales MJ; González J; Arribas JR; Carcas AJ; de la Oliva P; Borobia AM
    Trials; 2020 Jun; 21(1):466. PubMed ID: 32493475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.